1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      NDUFA4L2 reduces mitochondrial respiration resulting in defective lysosomal trafficking in clear cell renal cell carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          ABSTRACT

          In clear cell renal cell carcinoma (ccRCC), activation of hypoxic signaling induces NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 (NDUFA4L2) expression. Over 90% of ccRCCs exhibit overexpression of NDUFA4L2, which we previously showed contributes to ccRCC proliferation and survival. The function of NDUFA4L2 in ccRCC has not been fully elucidated. NDUFA4L2 was reported to reduce mitochondrial respiration via mitochondrial complex I inhibition. We found that NDUFA4L2 expression in human ccRCC cells increases the extracellular acidification rate, indicative of elevated glycolysis. Conversely, NDUFA4L2 expression in non-cancerous kidney epithelial cells decreases oxygen consumption rate while increasing extracellular acidification rate, suggesting that a Warburg-like effect is induced by NDUFA4L2 alone. We performed mass-spectrometry (MS)-based proteomics of NDUFA4L2 associated complexes. Comparing RCC4-P (parental) ccRCC cells with RCC4 in which NDUFA4L2 is knocked out by CRISPR-Cas9 (RCC4-KO-643), we identified 3,215 proteins enriched in the NDUFA4L2 immunoprecipitates. Among the top-ranking pathways were “Metabolic Reprogramming in Cancer” and “Glycolysis Activation in Cancer (Warburg Effect).” We also show that NDUFA4L2 enhances mitochondrial fragmentation, interacts with lysosomes, and increases mitochondrial-lysosomal associations, as assessed by high-resolution fluorescence microscopy and live cell imaging. We identified 161 lysosomal proteins, including Niemann-Pick Disease Type C Intracellular Cholesterol Transporters 1 and 2 (NPC1, NPC2), that are associated with NDUFA4L2 in RCC4-P cells. RCC4-P cells have larger and decreased numbers of lysosomes relative to RCC4 NDUFA4L2 knockout cells. These findings suggest that NDUFA4L2 regulates mitochondrial-lysosomal associations and potentially lysosomal size and abundance. Consequently, NDUFA4L2 may regulate not only mitochondrial, but also lysosomal functions in ccRCC.

          Related collections

          Most cited references51

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer Statistics, 2021

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2017) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2018) were collected by the National Center for Health Statistics. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths are projected to occur in the United States. After increasing for most of the 20th century, the cancer death rate has fallen continuously from its peak in 1991 through 2018, for a total decline of 31%, because of reductions in smoking and improvements in early detection and treatment. This translates to 3.2 million fewer cancer deaths than would have occurred if peak rates had persisted. Long-term declines in mortality for the 4 leading cancers have halted for prostate cancer and slowed for breast and colorectal cancers, but accelerated for lung cancer, which accounted for almost one-half of the total mortality decline from 2014 to 2018. The pace of the annual decline in lung cancer mortality doubled from 3.1% during 2009 through 2013 to 5.5% during 2014 through 2018 in men, from 1.8% to 4.4% in women, and from 2.4% to 5% overall. This trend coincides with steady declines in incidence (2.2%-2.3%) but rapid gains in survival specifically for nonsmall cell lung cancer (NSCLC). For example, NSCLC 2-year relative survival increased from 34% for persons diagnosed during 2009 through 2010 to 42% during 2015 through 2016, including absolute increases of 5% to 6% for every stage of diagnosis; survival for small cell lung cancer remained at 14% to 15%. Improved treatment accelerated progress against lung cancer and drove a record drop in overall cancer mortality, despite slowing momentum for other common cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Enrichr: a comprehensive gene set enrichment analysis web server 2016 update

            Enrichment analysis is a popular method for analyzing gene sets generated by genome-wide experiments. Here we present a significant update to one of the tools in this domain called Enrichr. Enrichr currently contains a large collection of diverse gene set libraries available for analysis and download. In total, Enrichr currently contains 180 184 annotated gene sets from 102 gene set libraries. New features have been added to Enrichr including the ability to submit fuzzy sets, upload BED files, improved application programming interface and visualization of the results as clustergrams. Overall, Enrichr is a comprehensive resource for curated gene sets and a search engine that accumulates biological knowledge for further biological discoveries. Enrichr is freely available at: http://amp.pharm.mssm.edu/Enrichr.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              On the origin of cancer cells.

              O WARBURG (1956)
                Bookmark

                Author and article information

                Journal
                Cancer Biol Ther
                Cancer Biol Ther
                Cancer Biology & Therapy
                Taylor & Francis
                1538-4047
                1555-8576
                1 February 2023
                2023
                1 February 2023
                : 24
                : 1
                : 2170669
                Affiliations
                [a ]Department of Pharmacology, Weill Cornell Medicine; , New York, NY, USA
                [b ]Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center; , New York, NY, USA
                [c ]Meyer Cancer Center, Weill Cornell Medicine; , New York, NY, USA
                [d ]Division of Regenerative Medicine Research, Department of Medicine, Weill Cornell Medicine; , New York, NY, USA
                [e ]Department of Biomedical Engineering, the City College of New York; , New York, NY, USA
                [f ]Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medicine; , New York, NY, USA
                [g ]Faculty of Medicine and Health Sciences, Center for Cancer Sciences, University of Nottingham, Sutton Bonington Campus; , Loughborough, UK
                [h ]Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medicine; , New York, NY, USA
                [i ]Department of Urology; New York Presbyterian Hospital, Weill Cornell Medicine; , New York, NY, USA
                Author notes
                CONTACT Lorraine J. Gudas ljgudas@ 123456med.cornell.edu Department of Pharmacology, Weill Cornell Medicine; , New York, NY 10065

                The authors declare no potential conflicts of interest.

                Author information
                https://orcid.org/0000-0003-3115-4777
                Article
                2170669
                10.1080/15384047.2023.2170669
                9897797
                36722045
                d42117e8-b9fa-40ff-ab15-0cd5280d10d2
                © 2023 Weill Cornell Medical College. Published with license by Taylor & Francis Group, LLC.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 6, Tables: 1, References: 52, Pages: 14
                Categories
                Research Article
                Research Paper

                Oncology & Radiotherapy
                ndufa4l2,ccrcc,lysosome,mitochondria,npc2,expansion microscopy,kidney cancer,mass spectrometry,co-immunofluorescence,glycolysis,oxidative phosphorylation,mitochondrial respiration,warburg effect,mistr2,mistr3,mircaf2,mircaf3,hypoxia,ndufa4,hif1a

                Comments

                Comment on this article